Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key

Nature

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

01-10-2019

Key

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Key

ESMO open

Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.

19-03-2025

ESMO open

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

01-01-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

02-12-2024

Nature genetics

Base editing screens define the genetic landscape of cancer drug resistance mechanisms.

01-11-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

03-09-2024

Cancer discovery

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells.

02-08-2024

The Journal of pathology

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

01-07-2024

Cancer treatment reviews

Agnostic drug development revisited.

01-07-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Acta oncologica (Stockholm, Sweden)

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).

23-05-2024

Acta oncologica (Stockholm, Sweden)

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

23-05-2024

Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024

The oncologist

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

03-05-2024

European journal of cancer (Oxford, England : 1990)

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).

01-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

01-04-2024

Cell

Generating and using real-world data: A worthwhile uphill battle.

28-03-2024

Nature protocols

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.

01-03-2024

Genetics in medicine : official journal of the American College of Medical Genetics

Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.

01-02-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

International journal of cancer

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

01-10-2023

Journal of internal medicine

Precision cancer medicine: Concepts, current practice, and future developments.

01-10-2023

Clinical advances in hematology & oncology : H&O

Repurposing drugs in oncology.

01-09-2023

The New England journal of medicine

Third-Line Therapy in Metastatic Colorectal Cancer.

13-07-2023

Cancer cell

Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

12-06-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

Cancer medicine

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

01-06-2023

Nature reviews. Clinical oncology

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

01-05-2023

ESMO open

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

01-04-2023

BMC cancer

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

04-03-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

01-03-2023

Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023

Cancer cell

Base editing screens map mutations affecting interferon-γ signaling in cancer.

13-02-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Journal of proteome research

Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation.

06-01-2023

ESMO open

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

01-12-2022

The Journal of pathology

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.

01-10-2022

European journal of cancer (Oxford, England : 1990)

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

01-08-2022

Cancer discovery

Can Drug Repurposing Accelerate Precision Oncology?

06-07-2022

Frontiers in medicine

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

02-07-2022

Cancer chemotherapy and pharmacology

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

01-07-2022

Cell reports. Medicine

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

21-06-2022

Nature cancer

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

01-05-2022

The Lancet. Oncology

The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply.

01-05-2022